APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice - PubMed (original) (raw)

APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice

Jacqueline Kunzler et al. Neurosci Lett. 2014.

Abstract

The post-menopausal loss of estrogen is key in the increased incidence of Alzheimer's disease (AD) in women. However, estrogen therapy (ET) clinical trials have produced conflicting results. The APOE gene of apolipoprotein E (apoE) likely modulates the effects of ET in AD. APOE4 is the greatest genetic risk factor for AD, increasing risk up to 15-fold compared with APOE3, and the negative effect of APOE4 on AD risk and neuropathology is greater in women than men. The interactive effects of APOE and ET may converge on modulation of amyloid-beta (Aβ) levels, as independently both the loss of estrogen and APOE4 increases Aβ accumulation. Thus, in this study, 3-month old female EFAD mice (5XFAD mice crossed with apoE-targeted replacement mice), which express increased levels of Aβ42 and human APOE were ovariectomized and treated for 3 months with either 17-β estradiol (OVX(ET+), 0.25mg total) or vehicle control (OVX(ET-)) and the effects on Aβ accumulation were determined. Compared to the OVX(ET-) cohort, in the OVX(ET+) cohort, extracellular amyloid and Aβ deposition in the hippocampus and cortex were decreased with APOE2 and APOE3, but were increased with APOE4 by IHC. Biochemical analysis demonstrated increased total and insoluble Aβ levels with APOE4, and decreased soluble Aβ42 levels with both APOE3 and APOE4, after ET. These data suggest that ET administered at menopause may benefit APOE4 negative women by decreasing extracellular and soluble Aβ42. However, for APOE4 carriers, the efficacy of ET will be dependent on the relative impact of extracellular and soluble Aβ on AD-induced neurodegeneration.

Keywords: AD; AD transgenic mouse model; APOE; Alzheimer's disease; Amyloid-β; Aβ; ET; Estrogen; FAD; HRT; OVX; OVX(ET+); OVX(ET−); Soluble Aβ; Thio-S; amyloid-β; apoE; apolipoprotein E; estrogen therapy; familial AD; hormone replacement therapy; ovariectomy; ovariectomy with ET; ovariectomy without ET; thioflavin S.

Copyright © 2014. Published by Elsevier Ireland Ltd.

PubMed Disclaimer

Figures

Figure 1

Figure 1. Extracellular amyloid plaque and Aβ deposition is decreased with APOE2 and APOE3 but increased with APOE4, in ovariectomized EFAD mice treated with estradiol

Representative image of sagittal sections from ovariectomized EFAD mice treated with vehicle (OVXET−) or estradiol (OVXET+), and A. stained with Thio-S or B. immunostained for Aβ (red) and NeuN (green) (x10 magnification). Quantification of number, size and % area covered in the frontal cortex of C. Thio-S stained plaque plaques or D. extracellular Aβ. Data are expressed as the mean ± S.E.M, and were analyzed by one-way ANOVA followed by Tukey’s multiple comparison post hoc analysis. n = 5–6. *p < 0.05 OVXET− versus OVXET+. #p < 0.05 vs E4FAD for OVXET−, ^p < 0.05 vs E4FAD for OVXET+

Figure 2

Figure 2. Total and insoluble Aβ42 levels are increased with APOE4, whereas soluble Aβ42 levels are decreased with APOE3 and APOE4 in ovariectomized EFAD mice treated with estradiol

A. Total Aβ42 levels in the CX, HC and CB of ovariectomized EFAD mice as measured by ELISA. Total Aβ42 levels in the B. hippocampus and C. cortex of ovariectomized EFAD mice treated with vehicle (OVXET−) or estradiol (OVXET+). Aβ42 extraction profile using a three-step sequential protein extraction (PBS, PBSX, Gu) in the D hippocampus and E. cortex. Data are expressed as the mean ± S.E.M, and were analyzed by one-way ANOVA followed by Tukey’s multiple comparison post hoc analysis. n = 5–6. *p < 0.05 OVXET− versus OVXET+. #p < 0.05 vs E4FAD for OVXET−, ^p < 0.05 vs E4FAD for OVXET+

Similar articles

Cited by

References

    1. Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, Dartigues JF, Kragh-Sorensen P, Baldereschi M, Brayne C, Lobo A, Martinez-Lage JM, Stijnen T, Hofman A. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology. 1999;53:1992–1997. - PubMed
    1. Bretsky PM, Buckwalter JG, Seeman TE, Miller CA, Poirier J, Schellenberg GD, Finch CE, Henderson VW. Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer disease and associated disorders. 1999;13:216–221. - PubMed
    1. Carroll JC, Rosario ER, Chang L, Stanczyk FZ, Oddo S, LaFerla FM, Pike CJ. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2007;27:13357–13365. - PMC - PubMed
    1. Corder EH, Ghebremedhin E, Taylor MG, Thal DR, Ohm TG, Braak H. The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Annals of the New York Academy of Sciences. 2004;1019:24–28. - PubMed
    1. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R, Hays J. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA : the journal of the American Medical Association. 2004;291:2959–2968. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources